Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01560416
Recruitment Status : Active, not recruiting
First Posted : March 22, 2012
Last Update Posted : February 22, 2018
Information provided by (Responsible Party):
Nancy Lin, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : December 2017
  Estimated Study Completion Date : December 2018